Objective evaluation of dextromethorphan and glaucine as antitussive agents.

Abstract

Twenty-four inpatients affected by chronic cough completed a single-dose double-blind cross-over study of placebo, glaucine 30 mg and dextromethorphan 30 mg. The study was carried out using a balanced incomplete block design, each patient receiving two of the three experimental treatments. Objective evaluation of cough was ensured by means of a writing cough recorder. Coughs after dextromethorphan and glaucine were fewer than coughs after placebo: however only glaucine was significantly different from placebo in reducing coughs. Treatments were well tolerated: clinical results included a reduction in pulse rate after both dextromethorphan and glaucine , and a large number of patients reporting side effects after dextromethorphan administration.

• Authors: K H Rühle, D Criscuolo, H A Dieterich, D Köhler, G Riedel
• Journal: British journal of clinical pharmacology (Br J Clin Pharmacol) Vol. 17 Issue 5 Pg. 521-4 (May 1984) ISSN: 0306-5251 [Print] England
• PMID: 6375709 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Antitussive Agents
• Aporphines
• Levorphanol
• Dextromethorphan
• glaucine

Topics

• Adult
• Aged
• Antitussive Agents (therapeutic use)
• Aporphines (therapeutic use)
• Clinical Trials as Topic
• Cough (drug therapy)
• Dextromethorphan (adverse effects, therapeutic use)
• Double-Blind Method
• Female
• Headache (chemically induced)
• Humans
• Levorphanol (analogs & derivatives)
• Male
• Middle Aged
• Pulse (drug effects)
• Random Allocation
• Sleep Wake Disorders (chemically induced)
• Vision Disorders (chemically induced)